Lipella reports positive Phase 2a results for LP-10 in oral lichen planus; all efficacy endpoints met

LIPELLA PHARMACEUTICALS INC.

All 27 patients completed 4-week treatment; no serious adverse events reported.
76% of tacrolimus blood measurements undetectable (<1.0 ng/mL); dry mouth in 18.5%.
Statistically significant improvements (p<0.05) in IGA, REU, pain, sensitivity, and OLPSSM at week 4.
Company advancing LP-10 into Phase 2b; preparing protocol with FDA feedback.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.